X

Trial Profile

A phase III trial of epitinib in first-line patients with EGFR-mutant NSCLC patients with brain metastasis

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epitinib (Primary)
Indications Brain metastases; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors HUTCHMED

Most Recent Events

06 Mar 2018 According to a Chi-Med media release, the company is preparing to initiate this pivotal study of epitinib in EGFR mutant NSCLC patients with brain metastasis in China in 2018.
18 Aug 2016 New trial record
02 Aug 2016 According to Chi-Med media release, company targets to initiate this pivotal registration study before the end of H1 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com